全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Effects of a Cocktail Supplement of Ginkgo Biloba and Acai Extract on Cognitive Symptoms of Parkinson’s Disease

DOI: 10.4236/apd.2024.133004, PP. 57-72

Keywords: Parkinson’s Disease (PD), Cognitive Function, Ginkgo Biloba, Acai Extract, Neurodegenerative Disorders, Natural Supplements, Cognitive Symptoms, Montreal Cognitive Assessment (MoCA), Dopaminergic Neurons, Antioxidants, Neuroprotection, Non-Motor Symptoms, Oxidative Stress, Polyphenols

Full-Text   Cite this paper   Add to My Lib

Abstract:

Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, including cognitive impairment. Current treatments often involve synthetic drugs with significant side effects and potential for dependency. This study investigates the effects of a natural supplement combination of Ginkgo Biloba and Acai Extract on cognitive symptoms in a 77-year-old male with PD. The participant underwent a three-month supplementation regimen, with cognitive function assessed using the Montreal Cognitive Assessment (MoCA) test before and after the intervention. The results indicated an improvement in cognitive scores, suggesting that the combination of Ginkgo Biloba and Acai Extract may offer a promising alternative or adjunct to conventional PD treatments. This study highlights the potential of natural supplements in managing PD symptoms and calls for further research with larger sample sizes to confirm these findings. Human data was performed in accordance with the Declaration of Helsinki by the Roxbury District IRB Board (IRB Number: IRB00011767).

References

[1]  Ciccarelli, S.K. and White, J.N. (2013) Psychology: Diagnostic and Statistical Manual of Mental Disorders. 5th Edition, Pearson.
[2]  Cosgrove, J., Alty, J.E. and Jamieson, S. (2015) Cognitive Impairment in Parkinson’s Disease. Postgraduate Medical Journal, 91, 212-220.
https://doi.org/10.1136/postgradmedj-2015-133247
[3]  Swanson, C.R., Sesso, S.L. and Emborg, M.E. (2009) Can We Prevent Parkinson’s Disease? Frontiers in Bioscience, 14, 1642-1660.
[4]  Roiser, J.P., Nathan, P.J., Mander, A.P., Adusei, G., Zavitz, K.H. and Blackwell, A.D. (2015) Assessment of Cognitive Safety in Clinical Drug Development.
https://discovery.ucl.ac.uk/1480983/
[5]  Gandhi, K.R. and Saadabadi, A. (2022) Levodopa (L-DOPA). StatPearls.
https://www.ncbi.nlm.nih.gov/books/NBK482140/
[6]  Punch, K. and Oancea, A. (2004) Introduction to Research Methods in Education. Sage Publications Ltd.
[7]  Hsu, W., Lane, H. and Lin, C. (2018) Medications Used for Cognitive Enhancement in Patients with Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease. Frontiers in Psychiatry, 9, Article 91.
https://doi.org/10.3389/fpsyt.2018.00091
[8]  Singh, A., Tripathi, P., Yadawa, A.K. and Singh, S. (2020) Promising Polyphenols in Parkinson’s Disease Therapeutics. Neurochemical Research, 45, 1731-1745.
https://doi.org/10.1007/s11064-020-03058-3
[9]  Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., et al. (2012) A Method for Generation Phage Cocktail with Great Therapeutic Potential. PLOS ONE, 7, e31698.
https://doi.org/10.1371/journal.pone.0031698
[10]  Schauss, A.G., Wu, X., Prior, R.L., Ou, B., Patel, D., Huang, D., et al. (2006) Phytochemical and Nutrient Composition of the Freeze-Dried Amazonian Palm Berry, Euterpe oleraceae Mart. (Acai). Journal of Agricultural and Food Chemistry, 54, 8598-8603.
https://doi.org/10.1021/jf060976g
[11]  Lama, J., Buhidma, Y., Fletcher, E.J.R. and Duty, S. (2021) Animal Models of Parkinson’s Disease: A Guide to Selecting the Optimal Model for Your Research. Neural Signaling, 5, NS20210026.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661507/
[12]  Rioux Bilan, A., Freyssin, A., Page, G. and Fauconneau, B. (2018) Natural Polyphenols Effects on Protein Aggregates in Alzheimer’s and Parkinson’s Prion-Like Diseases. Neural Regeneration Research, 13, 955-961.
https://doi.org/10.4103/1673-5374.233432
[13]  Trebatická, J. and Ďuračková, Z. (2015) Psychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy? Oxidative Medicine and Cellular Longevity, 2015, Article ID: 248529.
https://doi.org/10.1155/2015/248529
[14]  ALNasser, M.N., Mellor, I.R. and Carter, W.G. (2022) A Preliminary Assessment of the Nutraceutical Potential of Acai Berry (Euterpe sp.) as a Potential Natural Treatment for Alzheimer’s Disease. Molecules, 27, Article 4891.
https://doi.org/10.3390/molecules27154891
[15]  Guo, S., Yan, J., Yang, T., Yang, X., Bezard, E. and Zhao, B. (2007) Protective Effects of Green Tea Polyphenols in the 6-OHDA Rat Model of Parkinson’s Disease through Inhibition of ROS-NO Pathway. Biological Psychiatry, 62, 1353-1362.
https://doi.org/10.1016/j.biopsych.2007.04.020
[16]  Faria, A., Meireles, M., Fernandes, I., Santos-Buelga, C., Gonzalez-Manzano, S., Dueñas, M., et al. (2014) Flavonoid Metabolites Transport across a Human BBB Model. Food Chemistry, 149, 190-196.
https://doi.org/10.1016/j.foodchem.2013.10.095
[17]  Stevens, W. (2020) “Cocktail Therapy” May Benefit Individuals with Parkinson Disease Dementia.
https://www.ajmc.com/view/cocktail-therapy-may-benefit-individuals-with-parkinson-disease-dementia
[18]  Henderson, E.J., Chu, H., Gaunt, D.M., Whone, A.L., Ben-Shlomo, Y. and Lyell, V. (2016) Comparison of Test Your Memory and Montreal Cognitive Assessment Measures in Parkinson’s Disease. Parkinsons Disease, 2016, Article ID: 1012847.
https://doi.org/10.1155/2016/1012847
[19]  Zhu, W., Wadley, V.G., Howard, V.J., Hutto, B., Blair, S.N. and Hooker, S.P. (2017) Objectively Measured Physical Activity and Cognitive Function in Older Adults. Medicine & Science in Sports & Exercise, 49, 47-53.
https://doi.org/10.1249/mss.0000000000001079
[20]  (2020) Cognitive Testing: Medlineplus Medical Test.
https://medlineplus.gov/lab-tests/cognitive-testing/
[21]  Diamond, B.J., Shiflett, S.C., Feiwel, N., Matheis, R.J., Noskin, O., Richards, J.A., et al. (2000) Ginkgo Biloba Extract: Mechanisms and Clinical Indications. Archives of Physical Medicine and Rehabilitation, 81, 668-678.
https://doi.org/10.1016/s0003-9993(00)90052-2
[22]  Krishnan, K., Rossetti, H., Hynan, L.S., Carter, K., Falkowski, J., Lacritz, L., et al. (2016) Changes in Montreal Cognitive Assessment Scores over Time. Assessment, 24, 772-777.
https://doi.org/10.1177/1073191116654217
[23]  The Parkinson Study Group (2005) Levodopa and the Progression of Parkinson’s Disease. The New England Journal of Medicine, 351, 2498-2508.
https://www.nejm.org/doi/full/10.1056/NEJMoa033447
[24]  Sudman, S., Bradburn, N.M. and Schwarz, N. (1996) Thinking about Answers: The Application of Cognitive Processes to Survey Methodology. Jossey-Bass.
[25]  Matalonga, L., Arias, A., Coll, M.J., Garcia-Villoria, J., Gort, L. and Ribes, A. (2013) Treatment Effect of Coenzyme Q10 and an Antioxidant Cocktail in Fibroblasts of Patients with Sanfilippo Disease. Journal of Inherited Metabolic Disease, 37, 439-446.
https://doi.org/10.1007/s10545-013-9668-1
[26]  Liu, Q., Xiong, N., Gong, X., Tong, H., Tan, X. and Guo, X. (2022) Cocktail Therapy with Prednisolone, Vincristine and Sirolimus for Kasabach-Merritt Phenomenon in 10 Infants. Experimental and Therapeutic Medicine, 24, Article No. 621.
https://doi.org/10.3892/etm.2022.11558
[27]  Lenka, A. and Jankovic, J. (2023) How Should Future Clinical Trials Be Designed in the Search for Disease-Modifying Therapies for Parkinson’s Disease? Expert Review of Neurotherapeutics, 23, 107-122.
https://doi.org/10.1080/14737175.2023.2177535

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133